SEC Form 4 · accession 0001144204-17-038410
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chaim Lebovits
Officer — See Remarks
Period of report
Jul 26, 2017
Accepted (ET)
Jul 26, 2017 · 5:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 26, 2017 | A | 31,185 | $0.00 | A | 2,103,785 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $4.81 | Jul 26, 2017 | A | 41,580 | A | Jul 26, 2017 | Jul 26, 2019 | Common Stock | 41,580 | 41,580 | D |
Explanation of responses
- F1Shares acquired are shares of restricted stock awarded on July 26, 2017 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.
- F2Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 138,806 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares.
- F3Option is fully vested exercisable as of the date of grant and shall remain exercisable until the 2nd anniversary of the date of grant.
Remarks
Chief Executive Officer & President